Global Blood Screening Market is Growing at a Significant Rate in the Forecast Period 2018-2025

Global Blood Screening Market is expected to reach CAGR in the forecast period of 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Access Full Report : https://databridgemarketresearch.com/reports/global-blood-screening-market/

Drivers: Global Blood Screening Market

RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS:

Blood transfusion is an essential component of the health care field. It helps in saving millions of lives every year in both cases of routine and emergency conditions. Below mentioned are some of the statistics for blood donation and blood donors:

  • According to the World Health Organization (WHO), in 2017, it was reported that 112.5 million blood donations were collected from worldwide in which approximately half of the blood was collected from developed countries.
  • According to the World Health Organization (WHO), in 2017, it was reported that in 1000 people, the blood donation rate was 32.1 from high-income countries, 14.9 in upper-middle-income countries, 7.8 in lower-middle-income countries and 4.6 in low-income countries.
  • According to Australia Red cross blood service, 606,000 donors are there in Australia which are in 1,000 locations such as collection centres for blood donation available.

RISING PREVALENCE IN NUMBER OF DISEASES:

The prevalence of diseases and conditions such as Tuberculosis, HIV infection, Intestinal nematodes, diabetes mellitus, respiratory diseases, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and many others have increased considerably over a period of time.  As numbers of diseases are increasing there is requirement for blood screening and diagnosis for further treatment of diseases.

  • According to WHO, alpha and beta thalassaemias are found to be the most common inherited single-gene disorders around the world. This disorder is with the highest prevalence with malaria at the places where it is endemic.As per the study conducted in Iran, it was estimated that approximately 8,000 pregnancies with risk takes place every year.
  • In 2016, according to Centers for Disease Control and Prevention (CDC), at the end of 2015, it was estimated 1.1 million persons with age 13 or older were suffering from HIV infection in the U.S. with an estimation of 162,500 (15.0%) persons whose infections had not been diagnosed.
  • In February 2018, according to verywell health, in South Africa 5,600,000 of people were estimated with HIV in 2009. In the total population of 53 million, the HIV prevalence for South Africa is found to be 10.6%.

RISING NUMBER OF INITIATIVES BY VARIOUS GOVERNMENTS AND GOVERNMENT ASSOCIATIONS:

Blood is an essential requirement for health care as well as proper functioning of the health system. National AIDS Control Organization that comes under government association is a division of the Ministry of Health and Family welfare providing leadership to programme in order to control HIV/AIDS . Various organisations are taking initiatives to create awareness about many diseases like HIV/AIDS. For instance, India National Aids Control Organisation (NACO) conducted awareness for HIV/AIDS to ensure the provision of safe blood for the country since 1992.   Below mentioned are some of the government initiatives. 

  • In March 2018, Exosome Sciences, Inc. subsidiary of Aethlon Medical, Inc., started  the initiation of an Institutional Review Board (IRB) approved protocol in research study field. This initiation was incorporated  with involvement of a data-supported biomarker candidate as well as  retired NFL players which provided  potentially detection  and monitoring of  Chronic Traumatic Encephalopathy (CTE) in living individuals
  • In June 2018, according to Ministry of Health and Family Welfare (MoHFW), Government of India, World Blood Donor Day (WBDD) celebrated around the world each year on 14th June. This celebration was done to raise awareness for regular blood donations. The program was sponsored by WHO, by collaborating with the International Federation of Red Cross and Red Crescent Societies (IFRC), the International Federation of Blood Donor Organizations (FIODS) and the International Society of Blood Transfusion (ISBT).

Restraints:

LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES

Nucleic acid amplification technology (NAT) is helpful in determining safety and efficiency of mini-pool testing for various health related problems such as hepatitis C virus (HCV), human immunodeficiency virus (HIV) and other diseases.

  • In June 2014, a paper published by National Center for Biotechnology Information (NCBI), NAT is one of the advanced techniques, highly sensitive and has issues of high cost related to an infrastructure facility, equipment, consumables lacking in technical expertise for developing countries.
  • In April 2018, article published by Indian Journal of Pathology and Microbiology, in India, 10 × 10^6 units of blood collected every year. If the whole collected blood is NAT tested then the country will experience an additional cost of 30 × 10^7. The 3 × 10^8 means 300 million US dollar which is a much higher amount for the developing country to afford.

HIGH COST OF TECHNOLOGY AND INSTRUMENTS

A blood screening is a process where blood is tested to detect particular disease in humans. This screening process is carried out in clinical diagnostics specifically for the detection of diseases such as HIV, infection and many other problems related to human health.

Several equipments used such as immunoassay analyzers, chemistry analyzers, assay kits, andhaematology analyzers for the detection of various blood screening process. Specialized analyzers are used to perform assays which are less commonly performed. Typically assay kits are used as standard lab equipments such as a spectrophotometer, and other equipments for ELISA process. Blood Screening Instruments have high cost and also requires maintenance after some period of time.

  • Merck KGaA (Germany) provides Acetate Colorimetric Assay Kit can be used for 100 colorimetric tests cost for USD 560.615 dollar which is costly to perform tests in laboratory in low income countries. This test is useful for detection of acetate in serum, plasma and animal tissues.

Emerging Alternative Technologies

There are two alternative technologies for performing blood screening including gel test and solid-phase assays. These assays have emerged by providing accurate, reproducible blood bank testing. Both technologies provide increased safety along with decreased biohazardous waste. These technologies are fully automated that decreases the opportunities for human errors and other tasks during test performance.

  • Food and Drug Administration has provided approval for Gel technology which is used for ABO grouping including forward and reverse, Rh typing, antibody screening and identification.
  • Solid-phase technology is the Food and Drug Administration (FDA) approved technology for antibody identification, antibody screening and compatibility testing. The screening process i.e. solid phase technology is recommended for antibody detection of transfusion recipients.
  • Serologic screening is another alternative for the screening process that helps in diagnosing infectious diseases in the microbiology laboratory and other labs .
  • In July 2016, according to NCBI, 7 out of 4583 (0.15%) from Minnesota, 38 out of 13,757 (0.28%) of the donors from country New York and 11 out of 8363 (0.13%) from New Mexico were found repeat reactive by EIA. The serologic technology includes EIA technique which provides screening.
  • Multiple Marker Screening (MMS) is also an alternative technology into blood screening that measures specific substances in the blood of a pregnant woman’s mainly from a fetus and the placental tissue. According to The Trustees of the University of Pennsylvania, the MMS test detects about 80% of Down syndrome,

Opportunity: Global Blood Screening Market

INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING

The screening of blood involves the process that ensures whether the blood collected from people are safe or not. Based on the results of the screening, collected blood units are released for clinical research purpose or discarded if it has some contamination of bacteria or viruses or any other. For performing such screening there are different assays that help in determining the proper result.

Further with advancement, many of the other techniques are introduced with high benefits helping the market to grow in the upcoming days. The techniques are microbial screening and multiplexing technology.

  • Thermo Fisher Scientific (U.S.) provides microbial isolation and screening which include blood culture systems, clinical microbial identification, and microbiology specimen collection
  • In August 2015, Eurofins (France) launched accredited NGS tests useful for the identification of non-targeted microorganism. It helps in 16S rDNA screening for identifying the presence of microorganism communities in sample.
  • In July 2017, July 18, 2017–BD (Becton, Dickinson and Company) (U.S.) introduced new technologies which can automatically report and release negative urine cultures. This technology is transformed in the form of microbiology urine testing.

Challenges: Global Blood Screening Market

REDUCTION IN PRICE FOR TECHNOLOGY AND INSTRUMENT

Screening processes for blood detection is an important part of preventive medicine. There are screening tools that provides information of diseases so that proper treatment can be provided by reducing the symptoms and other consequences. It helps in improving the health outcomes of the population. The technology and the instrument for performing screening are found to be costly.

  • In July 2017, As per Thermo Fisher Scientific (U.S.), epidemiologists conducted national precision medicine initiatives that were focusing on clinical research data on genetic variation around East and South Asian populations. This screening technique is a new genotyping tool consisting of 750,000 or more than biomarkers related to rare diseases or any other diseases for the clinical research studies. Costs associated with this technology in gene sequencing continue to challenge the genomic centers.
  • The instrument or technology used in screening has high cost which is a challenge for many companies. There should be development of new techniques same as of this but with low pricing comprehensive, flexible digitization of healthcare processes with accurate results.

Major Players: Global Blood Screening Market

Some major player in this market are F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc. ,Siemens AG , Bio-Rad Laboratories, Inc., among others.